DR. ELLIE VIRTUE APPOINTED CEO AT ANIZOME® AS IT TAKES NEXT STEPS IN DEVELOPMENT
10th September, 2019
ANIZOME®, a company dedicated to the commercial application of microbiome science in animal health, has appointed Dr. Ellie Virtue as its CEO.
Dr. Virtue brings extensive scientific and commercial experience in start-up human and veterinary biotech companies to Anizome. She has provided consulting and business services to early-stage human and veterinary companies where her roles have included a wide range of functions including operations, commercialisation, R&D, project management and alliance management.
Scott Carter, Chief Scientific Officer at Anizome, commenting on the appointment said: “Ellie’s combination of academic background and broad experience across all business functions means she understands the impact of biotechnology on the animal health business and what it takes to get those products to the marketplace. I am confident that she will greatly enhance our efforts to translate cutting-edge research and discovery into innovative therapeutic solutions.”
Prior to joining Anizome, Dr. Virtue was Investment Manager at Stonehaven Incubate, one of Anizome’s founding partners, where she helped identify innovative human health technologies that have potential for the animal health market.
Dr. Virtue said: “Microbiome science is an exciting and fast-moving field with tremendous potential in animal health. Anizome’s animal microbiome platform bridges the gap between research and commercial solutions, meaning we can provide innovative technology and expert insight to generate creative breakthroughs. I’m delighted to have this opportunity to lead the company through its next stage of development.”
Dr. Virtue has a Master of Applied Finance from Macquarie University and a PhD from University of Melbourne. Her PhD research on zoonotic viruses was conducted at the Australian Animal Health Laboratory, the country’s leading high-containment biosecurity facility. From 2011 until 2017 she worked for the animal health monoclonal antibody company, Nexvet Biopharma, where her roles encompassed research and development, operations, alliance management and business development.